表紙
市場調査レポート

世界のヒトインスリン市場-薬剤 (生物製剤、バイオシミラー) 、タイプ、ブランド、送達デバイス (ペン、ペンニードル、注射器) 、用途 (1型糖尿病、2型糖尿病) - 市場予測 (〜2020年)

Human Insulin Market - Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Forecasts to 2020

発行 MarketsandMarkets 商品コード 348325
出版日 ページ情報 英文 183 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
世界のヒトインスリン市場-薬剤 (生物製剤、バイオシミラー) 、タイプ、ブランド、送達デバイス (ペン、ペンニードル、注射器) 、用途 (1型糖尿病、2型糖尿病) - 市場予測 (〜2020年) Human Insulin Market - Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Forecasts to 2020
出版日: 2016年01月04日 ページ情報: 英文 183 Pages
概要

世界のヒトインスリン市場は、2015年から2020年にかけてCAGR (複合年間成長率) 8.1%の伸びで成長し、2020年には391億3,000万米ドルの規模に達することが予測されています。2015年には、北米地域が世界のヒトインスリン市場において最も規模の大きい市場となる見込みです。同市場の成長は、糖尿病患者数の増加、糖尿病に至るリスク要因に晒される人口の増加、ヒトインスリン類似物に対する市場需要の拡大、ヒトインスリンのドラッグデリバリー (薬物送達) デバイスの分野における技術的発展、ならびに医療補償制度の改善などによって促進されます。

当レポートでは、世界のヒトインスリン市場を取り上げ、市場の概要、市場発展促進・阻害要因、市場における課題および機会を概括し、製品タイプ別・タイプ別・ブランド別・送達デバイス別・用途別・地域別に市場の現状と見通しについて調査分析するとともに、競合環境、主要企業のプロファイルをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 プレミアムインサイト

  • 世界のヒトインスリン市場 (2015〜2020年)
  • 世界のヒトインスリン薬剤市場の規模、タイプ別 (2015年)
  • 世界のヒトインスリン送達デバイス市場の規模、タイプ別 (2015〜2020年)
  • 世界のヒトインスリン薬剤市場、ブランド別 (2015年 VS 2020年)
  • 世界のヒトインスリン製品市場の規模、国別 (2015〜2020年)

第5章 市場概要

  • イントロダクション
  • 市場区分
  • 市場の発展
  • 市場動態
    • 市場発展促進要因
      • 糖尿病患者数の増加
    • ヒトインスリン類似物に対する市場需要の拡大
  • ヒトインスリン送達デバイスにおける技術的発展
  • 先進国における医療補償シナリオの改善
    • 市場発展阻害要因
      • 製品認可のための厳しい規制要件
    • 市場機会
      • 新興市場における医療インフラの拡充
    • 主要インスリン薬剤の特許期限切れの見込み
    • 課題
      • 高い製品製造コスト

第6章 産業に関する考察

  • イントロダクション
  • 産業動向
    • ヒトインスリンペンに対する市場需要の拡大
    • 新たなヒトインスリン療法のパイプライン開発に対する市場の関心の高まり
  • パイプライン分析
    • 企業別
    • 臨床試験段階別
    • ポーターのファイブフォース分析

第7章 世界のヒトインスリン市場、製品タイプ別

  • イントロダクション
  • ヒトインスリン薬剤
  • ヒトインスリン送達デバイス

第8章 世界のヒトインスリン市場、タイプ別

  • イントロダクション
  • インスリン類似物およびバイオシミラー (バイオ後続品)
    • 長期作用
    • 即効性
    • 予混合
  • ヒトインスリン生物製剤
    • 短期作用
    • 中時間作用
    • 予混合

第9章 世界のヒトインスリン市場、ブランド別

  • イントロダクション
  • インスリン類似物およびバイオシミラー
    • LANTUS
    • NOVORAPIDおよびNOVOLOG
  • HUMALOG
  • その他ブランド
  • ヒトインスリン生物製剤
    • ACTRAPID、MIXTARD、INSULATARD
    • HUMULIN
  • INSUMAN

第10章 世界のヒトインスリン市場、送達デバイス別

  • イントロダクション
  • ヒトインスリンペン
    • 再利用可能ペン
    • 使い捨てペン
  • ヒトインスリンペンニードル
    • 標準ペンニードル
    • 安全ペンニードル
  • ヒトインスリン注射器

第11章 世界のヒトインスリン市場、用途別

  • イントロダクション
  • 1型糖尿病
  • 2型糖尿病

第12章 ヒトインスリン市場、地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • その他欧州
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • その他アジア太平洋
  • その他地域 (ROW)

第13章 競合情勢

  • 概要
  • 市場シェア分析
    • ヒトインスリン薬剤市場
    • ヒトインスリン送達デバイス市場
  • 競合シナリオ
  • 最新動向
    • 地域拡大
    • 契約、提携、パートナーシップ
    • 新製品発表
    • 認知プログラム
    • 資金供与、奨学金
    • 戦略的買収

第14章 企業プロファイル (概要、業績、製品・サービス、戦略、最新動向)

  • イントロダクション
  • B. BRAUN MELSUNGEN AG
  • BECTON, DICKINSON AND COMPANY
  • BIOCON LIMITED
  • BIODEL INC.
  • ELI LILLY AND COMPANY
  • JULPHAR (別称:GULF PHARMACEUTICAL INDUSTRIES)
  • NOVO NORDISK A/S
  • SANOFI
  • WOCKHARDT LIMITED
  • YPSOMED AG

第15章 付録

図表

目次
Product Code: BT 3981

The global human insulin market is poised to reach ~USD 39.13 billion by 2020 growing at a CAGR of 8.1% from 2015 to 2020. North America is expected to hold the largest share of the global human insulin market in 2015. Market growth of human insulin products is being propelled by growing diabetes patient population, increasing population exposure to key risk factors leading to diabetes, rising market demand for human insulin analogs, technological advancements in the field of human insulin delivery devices, and favorable medical reimbursements. However, stringent regulatory requirements for product approval are restraining the growth of human insulin market. In addition, high product manufacturing costs is posing significant challenges for market growth during the forecast period.

In this report, the global human insulin market is segmented on the basis of basis of products (human insulin biologics, insulin analogs & biosimilars, and delivery devices), drug type (rapid-acting, intermediate-acting, long-acting, short-acting, and premixed), drug brand (Lantus, NovoRapid/Novolog, Humalog, Humulin, Insuman, Actrapid, Insulatard, Mixtard, and Other Biosimilar Brands), delivery devices [insulin pens (reusable & disposable), pen needles (standard & safety), and conventional syringes], and applications (type I diabetes & type II diabetes).

Human insulin drugs segment is expected to account for the larger share of the global human insulin market in 2015, followed by insulin delivery devices. Significant demand growth for human insulin drugs during the next five years is owing to factors such as increasing market accessibility of generic human insulin products worldwide, rising government initiatives to support the development and commercialization of effective biosimilars, growing R&D for drug discovery & development, and rising proportion of aging population in developed countries.

Geographically, North America (comprising the U.S. and Canada) is expected to command the largest share of the global human insulin market in 2015, followed by Europe. Asia-Pacific is also poised to grow at the highest CAGR during the forecast period, owing to factors such as growing diabetes prevalence in APAC (coupled with large diabetic & pre-diabetic patient population), strengthening distribution networks of global product manufacturers in the region, evolving regulatory framework for marketing approvals & medical reimbursements, and rising public awareness related to benefits offered by human insulin in diabetes treatment (as compared to anti-diabetic drugs & animal derived insulin).

The global human insulin market is highly competitive, with various global as well as local players. In 2014, the global human insulin devices market was dominated by Sanofi (France), Novo Nordisk A/S (Denmark), and Eli Lilly and Company (U.S.), which together accounted for ~89.0% of the human insulin market. Geographic expansion, new product launches, agreements, collaborations, partnerships, awareness campaigns, and offering research fund & grants are the major strategies adopted by most market players to achieve growth in the global human insulin market.

Reasons to Buy the Report:

From an insight perspective, this research report has focused on various levels of analysis such as market share analysis of the top ten players and company profiles, which together comprise and discuss the basic views on the competitive landscape, emerging and high-growth segments of the human insulin market, and high-growth regions and their respective drivers, restraints, challenges, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn help firms to garner higher market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the human insulin products offered by the top 10 players in the global market. The report analyzes the human insulin market by product, drug type, drug brand, delivery devices, and applications across key geographic regions
  • Product Development/Innovation: Detailed insights on upcoming human insulin products, product pipeline, research and development activities, and new product launches in the market
  • Market Development: Comprehensive information on lucrative emerging markets. The report analyzes the markets for various human insulin products across key geographic regions
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the global human insulin market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of leading players in the global human insulin market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH DATA
    • 2.1.1. SECONDARY DATA
      • 2.1.1.1. Key data from secondary sources
    • 2.1.2. PRIMARY DATA
      • 2.1.2.1. Key data from primary sources
      • 2.1.2.2. Breakdown of primaries
  • 2.2. MARKET SIZE ESTIMATION
    • 2.2.1. BOTTOM-UP APPROACH
    • 2.2.2. TOP-DOWN APPROACH
  • 2.3. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4. RESEARCH ASSUMPTIONS
    • 2.4.1. ASSUMPTIONS

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CURRENT MARKET SCENARIO
  • 3.3. FUTURE OUTLOOK
  • 3.4. CONCLUSION

4. PREMIUM INSIGHTS

  • 4.1. GLOBAL HUMAN INSULIN MARKET (2015-2020)
  • 4.2. GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY TYPE (2015)
  • 4.3. GLOBAL HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY TYPE (2015-2020)
  • 4.4. GLOBAL HUMAN INSULIN DRUGS MARKET, BY BRAND (2015 VS. 2020)
  • 4.5. GLOBAL HUMAN INSULIN PRODUCTS MARKET SIZE, BY COUNTRY (2015-2020)

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
  • 5.3. MARKET EVOLUTION
  • 5.4. MARKET DYNAMICS
    • 5.4.1. KEY MARKET DRIVERS
      • 5.4.1.1. Growth in the number of diabetic patients
      • 5.4.1.2. Rising market demand for human insulin analogs
      • 5.4.1.3. Technological advancements in human insulin delivery devices
      • 5.4.1.4. Favorable medical reimbursement scenario in developed countries
    • 5.4.2. KEY MARKET RESTRAINTS
      • 5.4.2.1. Stringent regulatory requirements for product approval
    • 5.4.3. KEY MARKET OPPORTUNITIES
      • 5.4.3.1. Expansion of healthcare infrastructure across Emerging markets
      • 5.4.3.2. Expected patent expiry of key human insulin drugs
    • 5.4.4. KEY MARKET CHALLENGE
      • 5.4.4.1. High product manufacturing costs

6. INDUSTRY INSIGHTS

  • 6.1. INTRODUCTION
  • 6.2. INDUSTRY TRENDS
    • 6.2.1. GROWING MARKET DEMAND FOR HUMAN INSULIN PENS
    • 6.2.2. INCREASING MARKET FOCUS ON THE PIPELINE DEVELOPMENT OF NOVEL HUMAN INSULIN THERAPIES
  • 6.3. PIPELINE ANALYSIS
    • 6.3.1. BY COMPANY
    • 6.3.2. BY CLINICAL TRIAL PHASE
    • 6.3.3. PORTER'S FIVE FORCE ANALYSIS
      • 6.3.3.1. Threat from new entrants
      • 6.3.3.2. Threat from substitutes
      • 6.3.3.3. Bargaining power of buyers
      • 6.3.3.4. Bargaining power of suppliers
      • 6.3.3.5. Intensity of competitive rivalry

7. GLOBAL HUMAN INSULIN MARKET, BY PRODUCT TYPE

  • 7.1. INTRODUCTION
  • 7.2. HUMAN INSULIN DRUGS
  • 7.3. HUMAN INSULIN DELIVERY DEVICES

8. GLOBAL HUMAN INSULIN DRUGS MARKET, BY TYPE

  • 8.1. INTRODUCTION
  • 8.2. INSULIN ANALOGS AND BIOSIMILARS
    • 8.2.1. LONG-ACTING
    • 8.2.2. RAPID-ACTING
    • 8.2.3. PREMIXED
  • 8.3. HUMAN INSULIN BIOLOGICS
    • 8.3.1. SHORT-ACTING
    • 8.3.2. INTERMEDIATE-ACTING
    • 8.3.3. PREMIXED

9. GLOBAL HUMAN INSULIN DRUGS MARKET, BY BRAND

  • 9.1. INTRODUCTION
  • 9.2. INSULIN ANALOGS AND BIOSIMILARS
    • 9.2.1. LANTUS
    • 9.2.2. NOVORAPID AND NOVOLOG
    • 9.2.3. HUMALOG
    • 9.2.4. OTHER BRANDS
  • 9.3. HUMAN INSULIN BIOLOGICS
    • 9.3.1. ACTRAPID, MIXTARD, AND INSULATARD
    • 9.3.2. HUMULIN
    • 9.3.3. INSUMAN

10. GLOBAL HUMAN INSULIN MARKET, BY DELIVERY DEVICE

  • 10.1. INTRODUCTION
  • 10.2. HUMAN INSULIN PENS
    • 10.2.1. REUSABLE PENS
    • 10.2.2. DISPOSABLE PENS
  • 10.3. HUMAN INSULIN PEN NEEDLES
    • 10.3.1. STANDARD PEN NEEDLES
    • 10.3.2. SAFETY PEN NEEDLES
  • 10.4. HUMAN INSULIN SYRINGES

11. GLOBAL HUMAN INSULIN MARKET, BY APPLICATION

  • 11.1. INTRODUCTION
  • 11.2. TYPE I DIABETES
  • 11.3. TYPE II DIABETES

12. HUMAN INSULIN MARKET, BY REGION

  • 12.1. INTRODUCTION
  • 12.2. NORTH AMERICA
    • 12.2.1. U.S.
    • 12.2.2. CANADA
  • 12.3. EUROPE
    • 12.3.1. GERMANY
    • 12.3.2. FRANCE
    • 12.3.3. U.K.
    • 12.3.4. REST OF EUROPE (ROE)
  • 12.4. ASIA-PACIFIC (APAC)
    • 12.4.1. JAPAN
    • 12.4.2. CHINA
    • 12.4.3. INDIA
    • 12.4.4. REST OF ASIA-PACIFIC (ROAPAC)
  • 12.5. REST OF THE WORLD (ROW)

13. COMPETITIVE LANDSCAPE

  • 13.1. OVERVIEW
  • 13.2. MARKET SHARE ANALYSIS
    • 13.2.1. HUMAN INSULIN DRUGS MARKET
    • 13.2.2. HUMAN INSULIN DELIVERY DEVICES MARKET
  • 13.3. COMPETITIVE SCENARIO
  • 13.4. RECENT DEVELOPMENTS
    • 13.4.1. GEOGRAPHICAL EXPANSIONS
    • 13.4.2. AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
    • 13.4.3. NEW PRODUCT LAUNCHES
    • 13.4.4. AWARENESS PROGRAMS
    • 13.4.5. FUNDING & SCHOLARSHIPS
    • 13.4.6. STRATEGIC ACQUISITIONS

14. COMPANY PROFILES (Overview, Financials, Products & Services, Strategy, & Developments)*

  • 14.1. INTRODUCTION
  • 14.2. B. BRAUN MELSUNGEN AG
  • 14.3. BECTON, DICKINSON AND COMPANY
  • 14.4. BIOCON LIMITED
  • 14.5. BIODEL INC.
  • 14.6. ELI LILLY AND COMPANY
  • 14.7. JULPHAR (ALSO KNOWN AS GULF PHARMACEUTICAL INDUSTRIES)
  • 14.8. NOVO NORDISK A/S
  • 14.9. SANOFI
  • 14.10. WOCKHARDT LIMITED
  • 14.11. YPSOMED AG

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

15. APPENDIX

  • 15.1. INSIGHTS OF INDUSTRY EXPERTS
  • 15.2. DISCUSSION GUIDE
  • 15.3. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 15.4. AVAILABLE CUSTOMIZATIONS
  • 15.5. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: KEY HUMAN INSULIN DRUGS: YEAR OF PATENT EXPIRY
  • TABLE 2: KEY HUMAN INSULIN THERAPIES UNDER PIPELINE DEVELOPMENT & COMMERCIALIZATION: 2005-2015
  • TABLE 3: HUMAN INSULIN PIPELINE: MAJOR COMPANIES INVOLVED
  • TABLE 4: HUMAN INSULIN PIPELINE: STAGES OF CLINICAL TRIAL
  • TABLE 5: GLOBAL HUMAN INSULIN MARKET SIZE, BY PRODUCT TYPE, 2013-2020 (USD MILLION)
  • TABLE 6: HUMAN INSULIN DRUGS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 7: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 8: GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 9: GLOBAL INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 10: INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 11: LONG-ACTING INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 12: RAPID-ACTING INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 13: PREMIXED INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 14: GLOBAL HUMAN INSULIN BIOLOGICS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
  • TABLE 15: HUMAN INSULIN BIOLOGICS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 16: SHORT-ACTING HUMAN INSULIN BIOLOGICS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 17: INTERMEDIATE-ACTING HUMAN INSULIN BIOLOGICS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 18: PREMIXED HUMAN INSULIN BIOLOGICS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 19: GLOBAL HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT TYPE, 2013-2020 (USD MILLION)
  • TABLE 20: GLOBAL INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE, BY BRAND, 2013-2020 (USD MILLION)
  • TABLE 21: INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 22: INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE FOR LANTUS, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 23: INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE FOR NOVORAPID AND NOVOLOG, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 24: INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE FOR HUMALOG, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 25: INSULIN ANALOGS AND BIOSIMILARS MARKET SIZE FOR OTHER BRANDS, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 26: GLOBAL HUMAN INSULIN BIOLOGICS MARKET SIZE, BY BRAND, 2013-2020 (USD MILLION)
  • TABLE 27: HUMAN INSULIN BIOLOGICS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 28: HUMAN INSULIN BIOLOGICS MARKET SIZE FOR ACTRAPID, MIXTARD, AND INSULATARD, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 29: HUMAN INSULIN BIOLOGICS MARKET SIZE FOR HUMULIN, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 30: HUMAN INSULIN BIOLOGICS MARKET SIZE FOR INSUMAN, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 31: GLOBAL HUMAN INSULIN MARKET SIZE, BY DELIVERY DEVICE, 2013-2020 (USD MILLION)
  • TABLE 32: GLOBAL HUMAN INSULIN PENS MARKET SIZE, BY PRODUCT TYPE, 2013-2020 (USD MILLION)
  • TABLE 33: HUMAN INSULIN PENS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 34: REUSABLE HUMAN INSULIN PENS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 35: DISPOSABLE HUMAN INSULIN PENS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 36: GLOBAL HUMAN INSULIN PEN NEEDLES MARKET SIZE, BY PRODUCT TYPE, 2013-2020 (USD MILLION)
  • TABLE 37: HUMAN INSULIN PEN NEEDLES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 38: HUMAN INSULIN STANDARD PEN NEEDLES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 39: HUMAN INSULIN SAFETY PEN NEEDLES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 40: HUMAN INSULIN SYRINGES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 41: HUMAN INSULIN MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 42: NORTH AMERICA: HUMAN INSULIN MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 43: NORTH AMERICA: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 44: NORTH AMERICA: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 45: NORTH AMERICA: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 46: U.S.: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 47: U.S.: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 48: U.S.: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 49: CANADA: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 50: CANADA: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 51: CANADA: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 52: EUROPE: HUMAN INSULIN MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 53: EUROPE: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 54: EUROPE: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 55: EUROPE: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 56: GERMANY: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 57: GERMANY: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 58: GERMANY: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 59: FRANCE: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 60: FRANCE: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 61: FRANCE: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 62: U.K.: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 63: U.K.: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 64: U.K.: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 65: ROE: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 66: ROE: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 67: ROE: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 68: APAC: HUMAN INSULIN MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 69: APAC: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 70: APAC: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 71: APAC: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 72: JAPAN: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 73: JAPAN: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 74: JAPAN: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 75: CHINA: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 76: CHINA: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 77: CHINA: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 78: INDIA: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 79: INDIA: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 80: INDIA: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 81: ROAPAC: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 82: ROAPAC: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 83: ROAPAC: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 84: ROW: HUMAN INSULIN MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 85: ROW: HUMAN INSULIN DRUGS MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 86: ROW: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)
  • TABLE 87: GEOGRAPHICAL EXPANSIONS, 2012-2015
  • TABLE 88: AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS, 2012-2015
  • TABLE 89: NEW PRODUCT LAUNCHES AND PRODUCT APPROVALS, 2012-2015
  • TABLE 90: AWARENESS PROGRAMS, 2012-2015
  • TABLE 91: FUNDING & SCHOLARSHIPS, 2012-2015
  • TABLE 92: STRATEGIC ACQUISITIONS, 2012-2015

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: BOTTOM-UP APPROACH
  • FIGURE 3: TOP-DOWN APPROACH
  • FIGURE 4: DATA TRIANGULATION
  • FIGURE 5: ASSUMPTIONS FOR THE RESEARCH STUDY
  • FIGURE 6: HUMAN INSULIN MARKET SHARE, BY KEY PLAYER, 2014
  • FIGURE 7: FUTURE TRENDS: HUMAN INSULIN MARKET SIZE, BY PRODUCT (2015-2020)
  • FIGURE 8: FUTURE TRENDS: HUMAN INSULIN DRUGS MARKET SHARE, BY TYPE (2015 VS. 2020)
  • FIGURE 9: FUTURE TRENDS: HUMAN INSULIN DRUGS MARKET SIZE, BY BRAND (2015-2020)
  • FIGURE 10: FUTURE TRENDS: HUMAN INSULIN DELIVERY DEVICES MARKET SIZE, BY PRODUCT TYPE (2015-2020)
  • FIGURE 11: FUTURE TRENDS: HUMAN INSULIN MARKET SHARE, BY REGION (2015)
  • FIGURE 12: ATTRACTIVE GROWTH OPPORTUNITIES IN THE HUMAN INSULIN MARKET
  • FIGURE 13: NORTH AMERICA IS EXPECTED TO DOMINATE THE HUMAN INSULIN MARKET IN 2015
  • FIGURE 14: NORTH AMERICA TO COMMAND THE LARGEST SHARE OF ALL SEGMENTS OF THE HUMAN INSULIN DELIVERY DEVICES MARKET IN 2015
  • FIGURE 15: LANTUS IS EXPECTED TO BE THE LEADING INSULIN ANALOG TILL 2020
  • FIGURE 16: CHINA AND INDIA TO LEAD THE MARKET DEMAND FOR HUMAN INSULIN PRODUCTS DURING THE FORECAST PERIOD
  • FIGURE 17: MARKET EVOLUTION OF HUMAN INSULIN PRODUCTS
  • FIGURE 18: HUMAN INSULIN MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
  • FIGURE 19: GROWTH IN DIABETIC PATIENT POPULATION ACROSS KEY WHO REGIONS (2000-2030)
  • FIGURE 20: PROPORTION OF GERIATRIC POPULATION, BY COUNTRY (2012 VS. 2020)
  • FIGURE 21: GLOBAL TREND IN GOVERNMENT HEALTHCARE EXPENDITURE: DEVELOPED VS. DEVELOPING COUNTRIES (2010-2012)
  • FIGURE 22: PORTER'S FIVE FORCES ANALYSIS (2014): INCREASING NUMBER OF NEW PRODUCT MANUFACTURERS INCREASES MARKET COMPETITION
  • FIGURE 23: DELIVERY DEVICES POISED TO GROW AT THE HIGHEST RATE DURING 2015-2020
  • FIGURE 24: U.S. & EUROPE LEAD GLOBALLY, IN TERMS OF THE NUMBER OF ONGOING HUMAN INSULIN-BASED CLINICAL STUDIES (2015)
  • FIGURE 25: LONG-ACTING DRUGS TO LEAD THE INSULIN ANALOGS AND BIOSIMILARS MARKET TILL 2020
  • FIGURE 26: ASIA-PACIFIC IS POISED TO BE THE FASTEST GROWING MARKET FOR LONG-ACTING INSULIN ANALOGS AND BIOSIMILAR PRODUCTS DURING FORECAST PERIOD
  • FIGURE 27: INTERMEDIATE-ACTING DRUGS WILL CONTINUE TO DOMINATE THE HUMAN INSULIN BIOLOGICS MARKET TILL 2020
  • FIGURE 28: NORTH AMERICA IS EXPECTED TO DOMINATE THE INTERMEDIATE-ACTING HUMAN INSULIN BIOLOGICS MARKET DURING THE STUDY PERIOD
  • FIGURE 29: INSULIN ANALOGS & BIOSIMILAR DRUGS POISED TO GROW AT THE FASTEST RATE
  • FIGURE 30: LANTUS EXPECTED TO HOLD THE LARGEST SHARE OF INSULIN ANALOGS & BIOSIMILAR BRANDS MARKET TILL 2020
  • FIGURE 31: ASIA-PACIFIC POISED TO BE THE FASTEST-GROWING MARKET FOR NOVORAPID DURING THE FORECAST PERIOD
  • FIGURE 32: HUMULIN IS POISED TO BE THE FASTEST-GROWING HUMAN INSULIN BIOLOGICS BRANDS DURING 2015-2020
  • FIGURE 33: INSULIN PENS TO DOMINATE THE HUMAN INSULIN DELIVERY DEVICES MARKET DURING THE FORECAST PERIOD (2015-2020)
  • FIGURE 34: APAC TO DOMINATE THE HUMAN INSULIN PEN NEEDLES MARKET BY 2020
  • FIGURE 35: INDIA WILL HAVE THE HIGHEST DIABETES POPULATION BY 2030
  • FIGURE 36: MARKET TRENDS: NORTH AMERICAN HUMAN INSULIN MARKET (2015-2020)
  • FIGURE 37: MARKET TRENDS: EUROPEAN HUMAN INSULIN MARKET (2015-2020)
  • FIGURE 38: ASIA-PACIFIC HUMAN INSULIN MARKET SNAPSHOT, 2015-2020
  • FIGURE 39: LEADING PLAYERS ADOPTED THE STRATEGY OF GEOGRAPHIC EXPANSIONS TO STRENGTHEN THEIR MARKET POSITIONING DURING 2012 TO 2015
  • FIGURE 40: GLOBAL HUMAN INSULIN MARKET SHARE, BY KEY PLAYER (2014)
  • FIGURE 41: GLOBAL HUMAN INSULIN DRUGS MARKET RANKING, BY KEY PLAYER (2014)
  • FIGURE 42: GLOBAL HUMAN INSULIN DELIVERY DEVICES MARKET RANKING, BY KEY PLAYER (2014)
  • FIGURE 43: CONTINUOUS GEOGRAPHIC EXPANSION IS STIMULATING MARKET COMPETITION FOR CAPACITY BUILDING AMONG KEY PLAYERS
  • FIGURE 44: GEOGRAPHIC REVENUE MIX OF THE TOP 5 MARKET PLAYERS* (2014)
  • FIGURE 45: LEADING COMPANIES ARE FOCUSING ON CAPACITY BUILDING TO STRENGTHEN THEIR PRODUCT DEVELOPMENT & MANUFACTURING BASE
  • FIGURE 46: LEADING HUMAN INSULIN MANUFACTURERS ARE FOCUSING ON PRODUCT COMMERCIALIZATION TO STRENGTHEN THEIR MARKET POSITION
  • FIGURE 47: B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT
  • FIGURE 48: BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
  • FIGURE 49: BIOCON LIMITED: COMPANY SNAPSHOT
  • FIGURE 50: ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • FIGURE 51: JULPHAR: COMPANY SNAPSHOT
  • FIGURE 52: NOVO NORDISK A/S: COMPANY SNAPSHOT
  • FIGURE 53: SANOFI: COMPANY SNAPSHOT
  • FIGURE 54: WOCKHARDT LIMITED: COMPANY SNAPSHOT
  • FIGURE 55: YPSOMED AG: COMPANY SNAPSHOT
Back to Top